Опубликована: Янв. 1, 2024
Язык: Английский
Journal of Controlled Release, Год журнала: 2024, Номер 366, С. 519 - 534
Опубликована: Янв. 11, 2024
Язык: Английский
Процитировано
37
International Journal of Biological Sciences, Год журнала: 2024, Номер 20(4), С. 1332 - 1355
Опубликована: Янв. 1, 2024
Polyphenolic compounds have shown promising neuroprotective properties, making them a valuable resource for identifying prospective drug candidates to treat several neurological disorders (NDs).Numerous studies reported that polyphenols can disrupt the nuclear factor kappa B(NF-κB) pathway by inhibiting phosphorylation or ubiquitination of signaling molecules, which further prevents degradation IκB.Additionally, they prevent NF-κB translocation nucleus and pro-inflammatory cytokine production.Polyphenols such as curcumin, resveratrol, pterostilbene had significant inhibitory effects on NF-κB, treating NDs.Recent experimental findings suggest possess wide range pharmacological properties.Notably, much attention has been directed towards their potential therapeutic in NDs Alzheimer's disease (AD), Parkinson's (PD), cerebral ischemia, anxiety, depression, autism, spinal cord injury (SCI).Much preclinical data supporting neurotherapeutic benefits developed.Nevertheless, this study described significance agents, specifically emphasizing impact pathway.This article offers comprehensive analysis involvement NDs, including both clinical perspectives.
Язык: Английский
Процитировано
27
Advanced Healthcare Materials, Год журнала: 2024, Номер 13(12)
Опубликована: Янв. 11, 2024
Abstract Brain cancers, especially glioblastoma multiforme, are associated with poor prognosis due to the limited efficacy of current therapies. Nanomedicine has emerged as a versatile technology treat various diseases, including and played an indispensable role in combatting COVID‐19 pandemic evidenced by that lipid nanocarrier‐based vaccines have played. The tunability nanocarrier physicochemical properties —including size, shape, surface chemistry, drug release kinetics— resulted development wide range nanocarriers for brain cancer treatment. These can improve pharmacokinetics drugs, increase blood‐brain barrier transfer efficiency, specifically target cells. unique features would potentially allow more efficient treatment fewer side effects better therapeutic outcomes. This review provides overview options, challenges latest advances nanomedicine strategies investigated emphasis on targeted stimulus‐responsive their potential clinical translation.
Язык: Английский
Процитировано
15
Neurochemical Research, Год журнала: 2024, Номер 49(8), С. 1926 - 1944
Опубликована: Июнь 1, 2024
Язык: Английский
Процитировано
8
International Journal of Nanomedicine, Год журнала: 2024, Номер Volume 19, С. 4857 - 4875
Опубликована: Май 1, 2024
Abstract: Brain diseases are the most devastating problem among world's increasingly aging population, and number of patients with neurological is expected to increase in future. Although methods for delivering drugs brain have advanced significantly, none these approaches provide satisfactory results treatment diseases. This remains a challenge due unique anatomy physiology brain, including tight regulation limited access substances across blood-brain barrier. Nanoparticles considered an ideal drug delivery system hard-to-reach organs such as brain. The development new nanomaterial-based treatments has opened various opportunities scientists develop brain-specific systems that could improve outcomes disorders Alzheimer's disease, Parkinson's stroke tumors. In this review, we discuss noteworthy literature examines recent developments brain-targeted nanomedicines used Keywords: delivery, barrier, targeted nanoparticle, neurodegenerative diseases, stroke, cancer
Язык: Английский
Процитировано
5
Pharmaceutics, Год журнала: 2022, Номер 14(12), С. 2719 - 2719
Опубликована: Дек. 5, 2022
It is well known that the presence of a blood–brain barrier (BBB) makes drug delivery to brain more challenging. There are various mechanistic routes through which therapeutic molecules travel and deliver across BBB. Among all routes, transcellular route widely explored therapeutics. Advances in nanotechnology have encouraged scientists develop novel formulations for delivery. In this article, we broadly discussed BBB as limitation ways solve it using techniques such nanomedicine, nose-to-brain delivery, peptide carrier. addition, article will help understand different factors governing permeability BBB, formulation-related body clearance delivered into brain.
Язык: Английский
Процитировано
22
Journal of Cellular Physiology, Год журнала: 2023, Номер 238(2), С. 459 - 474
Опубликована: Янв. 4, 2023
Abstract Dysregulation of adult hippocampal neurogenesis is linked to major depressive disorder (MDD), with more than 300 million people diagnosed and worsened by the COVID‐19 pandemic. Accumulating evidence for neuropeptide Y (NPY) galanin (GAL) interaction was shown in various limbic system regions at molecular‐, cellular‐, behavioral‐specific levels. The purpose current work evaluate proliferating role GAL2 receptor (GALR2) Y1R agonists upon intranasal infusion ventral hippocampus. We studied their actions using cell nuclear antigen (PCNA) on neuroblasts or stem cells expression brain‐derived neurothrophic factor (BDNF). Moreover, we formation Y1R–GALR2 heteroreceptor complexes analyzed morphological changes neuronal cells. Finally, functional outcome NPY GAL hippocampus evaluated forced swimming test. demonstrated that GALR2 promotes proliferation dentate gyrus induction neurotrophic BDNF. These effects were mediated increased complexes, which may mediate neurites outgrowth observed Importantly, BDNF action found necessary antidepressant‐like after administration. Our data suggest translational development new heterobivalent agonist pharmacophores acting heterocomplexes novel therapy MDD depressive‐affecting diseases.
Язык: Английский
Процитировано
12
Pharmaceutics, Год журнала: 2025, Номер 17(1), С. 128 - 128
Опубликована: Янв. 17, 2025
Alzheimer's disease (AD) represents an escalating global health crisis, constituting the leading cause of dementia among elderly and profoundly impairing their quality life. Current FDA-approved drugs, such as rivastigmine, donepezil, galantamine, memantine, offer only modest symptomatic relief are frequently associated with significant adverse effects. Faced this challenge in line advances understanding pathophysiology neurodegenerative condition, various innovative therapeutic strategies have been explored. Here, we review novel approaches inspired by advanced knowledge underlying pathophysiological mechanisms disease. Among alternatives, immunotherapy stands out, employing monoclonal antibodies to specifically target eliminate toxic proteins implicated AD. Additionally, use medicinal plants is examined, synergistic effects components may confer neuroprotective properties. The modulation gut microbiota also addressed a peripheral strategy that could influence neuroinflammatory degenerative processes brain. Furthermore, potential emerging approaches, microRNAs regulate key cellular nanotherapy, which enables precise drug delivery central nervous system, analyzed. Despite promising these strategies, incidence continues rise. Therefore, it proposed achieving effective treatment future require integration combined maximizing different interventions.
Язык: Английский
Процитировано
0
Pharmaceutics, Год журнала: 2025, Номер 17(3), С. 280 - 280
Опубликована: Фев. 20, 2025
Central nervous system (CNS) diseases, such as brain tumors, Alzheimer’s disease, and Parkinson’s significantly impact patients’ quality of life impose substantial economic burdens on society. The blood–brain barrier (BBB) limits the effective delivery most therapeutic drugs, especially natural products, despite their potential effects. Trojan Horse strategy, using nanotechnology to disguise drugs “cargo”, enables them bypass BBB, enhancing targeting efficacy. This review explores applications products in treatment CNS discusses challenges posed by analyzes advantages limitations strategy. Despite existing technical challenges, future research is expected enhance application integrating nanotechnology, improving mechanisms, optimizing characteristics.
Язык: Английский
Процитировано
0
Journal of Nanobiotechnology, Год журнала: 2025, Номер 23(1)
Опубликована: Март 6, 2025
Synthetic biology and nanotechnology fusion represent a transformative approach promoting fundamental clinical biomedical science development. In SynBioNanoDesign, biological systems are reimagined as dynamic programmable materials to yield engineered nanomaterials with emerging specific functionalities. This review elucidates comprehensive examination of synthetic biology's pivotal role in advancing for targeted drug delivery systems. It begins exploring the synergy between nanotechnology, then highlights current landscape applications. Subsequently, discusses design novel informed by principles, focusing on expounding tools potential developing advanced nanomaterials. Afterward, research advances innovative through were systematically summarized, emphasizing integration genetic circuitry program nanomaterial responses. Furthermore, challenges, weaknesses opportunities, prospective directions, ethical societal implications SynBioNanoDesign elucidated. Finally, summarizes impact that may have drug-delivery technologies future.
Язык: Английский
Процитировано
0